Journal of Drug Targeting最新文献_第3页

Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus. 分离胰岛素联合地特胰岛素及二甲双胍对新诊断2型糖尿病患者胰岛功能的影响。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-04-02 DOI: 10.1080/1061186X.2025.2477074

Hui Wang, Shang Li, Tianqi Zhao, Xixi Pan, Liangxue Wang

{"title":"Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus.","authors":"Hui Wang, Shang Li, Tianqi Zhao, Xixi Pan, Liangxue Wang","doi":"10.1080/1061186X.2025.2477074","DOIUrl":"10.1080/1061186X.2025.2477074","url":null,"abstract":"This trial evaluated the effects of insulin aspart (IAsp) and insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus (T2DM). A total of 96 T2DM patients were randomised into the control group (insulin detemir + metformin treatment) and the study group (insulin detemir + metformin + IAsp treatment), with 48 cases each. The study compared clinical outcomes, as well as changes in fasting plasma glucose (FPG), 2-hour postprandial blood glucose (PBG), glycated haemoglobin (HbA1c), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), HOMA-β, quality of life, and sleep quality scores before and after treatment. Compared to the control group, the study group showed a higher total effective treatment rate, lower levels of FPG, 2-hour PBG, HbA1c, FINS, HOMA-IR, and sleep quality scores, while demonstrating higher HOMA-β and quality of life scores (all p < 0.05). Insulin detemir + metformin + IAsp was effective in treating T2DM, significantly enhancing insulin function and blood glucose levels, quality of life, and sleep quality. This combination therapy, though not commonly utilised in newly diagnosed T2DM patients, offers a novel therapeutic approach in clinical practice.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1394-1398"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent progress in chitosan-based nanoparticles for drug delivery: a review on modifications and therapeutic potential. 壳聚糖基纳米药物递送材料的研究进展：修饰和治疗潜力综述。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-05-14 DOI: 10.1080/1061186X.2025.2502956

Kevser Bal, Sibel Küçükertuğrul Çelik, Sema Şentürk, Özlem Kaplan, Emine Büşra Eker, Mehmet Koray Gök

{"title":"Recent progress in chitosan-based nanoparticles for drug delivery: a review on modifications and therapeutic potential.","authors":"Kevser Bal, Sibel Küçükertuğrul Çelik, Sema Şentürk, Özlem Kaplan, Emine Büşra Eker, Mehmet Koray Gök","doi":"10.1080/1061186X.2025.2502956","DOIUrl":"10.1080/1061186X.2025.2502956","url":null,"abstract":"Chitosan, obtained from chitin by deacetylation, is a versatile biopolymer known for its biocompatibility, biodegradability and environmental friendliness. Combined with its chemical and physical modifiability, these properties have made chitosan an important material in biomedical and pharmaceutical fields, especially in drug delivery systems. Chitosan-based nanomaterials exhibit enhanced functions through various chemical modifications such as thiolation, acetylation, carboxylation and phosphorylation, as well as through physical and enzymatic approaches. These modifications address inherent limitations such as poor solubility, limited acid resistance and insufficient mechanical strength, expanding the applications of chitosan in tissue engineering, gene therapy, vaccine delivery, wound healing and bioimaging. This review provides an in-depth analysis of the chemical structure, physicochemical properties and modification strategies of chitosan. It also explores current methodologies for preparing chitosan nanoparticles, along with drug loading and release techniques. Various targeting strategies employed in chitosan-based delivery systems are examined in detail. To illustrate the clinical relevance of these approaches, representative examples from recent therapeutic studies are included. Moreover, it highlights future research directions and the innovation potential of chitosan-based materials.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1366-1393"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel therapeutic approaches for non-small cell lung cancer: an updated view. 非小细胞肺癌的新治疗方法：最新观点。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-04-14 DOI: 10.1080/1061186X.2025.2489986

Niloufar Orooji, Shabnam Babaei, Manouchehr Fadaee, Hajar Abbasi-Kenarsari, Majid Eslami, Tohid Kazemi, Bahman Yousefi

{"title":"Novel therapeutic approaches for non-small cell lung cancer: an updated view.","authors":"Niloufar Orooji, Shabnam Babaei, Manouchehr Fadaee, Hajar Abbasi-Kenarsari, Majid Eslami, Tohid Kazemi, Bahman Yousefi","doi":"10.1080/1061186X.2025.2489986","DOIUrl":"10.1080/1061186X.2025.2489986","url":null,"abstract":"Non-small cell lung cancer (NSCLC) continues to be one of the leading causes of cancer-related mortality globally. Most patients who undergo surgical procedures may encounter distant metastasis or local recurrence, necessitating supplementary treatments such as radiation therapy, chemotherapy, or targeted therapy as adjuvant alternatives. Recent advancements in molecular biology and immunotherapy have paved the way for innovative therapeutic approaches that target specific genetic mutations and promote the immune response against tumour cells. This review explores emerging therapies, including targeted therapies such as tyrosine kinase inhibitors (TKIs) for actionable mutations (e.g., EGFR, ALK, ROS1), as well as the role of immune checkpoint inhibitors (ICIs) that employ the body's immune system to combat cancer. Additionally, we discuss the potential of exosome therapies, as well as promising nanotherapeutic options for the treatment of NSCLC. This study attempts to provide a thorough overview of the changing landscape of NSCLC treatment and its implications for enhancing patient outcomes by presenting these innovative techniques.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1306-1321"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer. egfr突变的非小细胞肺癌克服奥西替尼耐药的策略。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 DOI: 10.1080/1061186X.2025.2552431

Qiong Jiang, Yanxia Jin, Weidong Wang, Ying Chen, Leyi Tian, Xiaoyu Wang, Aobo Wu, Ruizhi Tian, Jicheng Pan, Yongsheng Gong

{"title":"Strategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer.","authors":"Qiong Jiang, Yanxia Jin, Weidong Wang, Ying Chen, Leyi Tian, Xiaoyu Wang, Aobo Wu, Ruizhi Tian, Jicheng Pan, Yongsheng Gong","doi":"10.1080/1061186X.2025.2552431","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2552431","url":null,"abstract":"Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has significantly advanced the treatment of non-small cell lung cancer (NSCLC), particularly in patients who develop resistance to first- and second-generation EGFR-TKIs. However, most patients inevitably develop resistance to the treatment, which presents a major challenge for long-term disease control. The molecular mechanisms underlying osimertinib resistance are complex and are generally categorised into EGFR-dependent and EGFR-independent pathways. To address this issue, various therapeutic strategies have been explored. These include the development of fourth-generation EGFR-TKIs, novel targeted agents and combination therapies involving molecular inhibitors, chemotherapeutic drugs, immunotherapeutic agents and gene inhibitors. In addition, nanomaterials, particularly selenium nanoparticles (SeNPs), have emerged as promising tools to overcome drug resistance. These nanomaterials can be used to enhance osimertinib delivery, improve its bioavailability, and modulate key resistance pathways at the cellular and molecular levels. This review comprehensively summarises the current understanding of resistance mechanisms to osimertinib and highlights cutting-edge therapeutic approaches. Special attention is given to nanotechnology-based strategies, which offer new possibilities for personalised and precise treatment of NSCLC. A deeper insight into these molecular mechanisms is essential for improving the clinical efficacy of osimertinib and prolonging the survival of patients with EGFR-mutant NSCLC.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-14"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design and formulation of fast-dissolving microneedles for the rapid transdermal delivery of lorazepam. 劳拉西泮快速透皮给药快溶微针的设计与制备。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-04-03 DOI: 10.1080/1061186X.2025.2483720

Punith M, Rajamma A J, Sateesha S B, Durgashree Diwakar, Girija E K, Chethan Kumar K B, Ankith N A, Mousam Bhowmik, Manjunatha P M

{"title":"Design and formulation of fast-dissolving microneedles for the rapid transdermal delivery of lorazepam.","authors":"Punith M, Rajamma A J, Sateesha S B, Durgashree Diwakar, Girija E K, Chethan Kumar K B, Ankith N A, Mousam Bhowmik, Manjunatha P M","doi":"10.1080/1061186X.2025.2483720","DOIUrl":"10.1080/1061186X.2025.2483720","url":null,"abstract":"This study investigates lorazepam-loaded dissolving microneedles (LMNs) as a fast-acting and minimally invasive treatment for status epilepticus. The LMNs were developed using a micro-moulding technique with an optimised combination of PVP K30, Dextran 40 and Pullulan. Their stability was confirmed through Fourier transform infra-red (FTIR) spectroscopy and X-ray diffraction (XRD) analysis. The Parafilm® membrane insertion test demonstrated 100% penetration efficiency, verifying their ability to effectively pierce the skin. Scanning electron microscopy (SEM) imaging revealed well-defined microneedles with precise dimensions (800 µm height, 200 µm base and 500 µm pitch). The LMNs rapidly dissolved in the subdermal layer of porcine skin. An ex vivo drug diffusion study showed that 3-5% of the encapsulated lorazepam was released within 30 min, with a cumulative release of 79.3% over 24 h. An acute dermal irritation study confirmed the biocompatibility and skin tolerance of the LMNs. Additionally, an in vivo anti-convulsant efficacy study in Albino Wistar rats subjected to maximal electroshock seizures demonstrated significant anticonvulsant effects (p < .05), confirming efficient systemic delivery of lorazepam. These findings highlight LMNs as a rapid-acting, non-invasive transdermal drug delivery system for managing status epilepticus, particularly in ambulatory care settings.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1399-1411"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineered extracellular vesicle with RAGE-antagonist peptide for delivery of anti-miRNA155 oligonucleotides to inflammatory lung cells. rage -拮抗剂肽工程细胞外囊泡用于向炎性肺细胞递送抗mirna155寡核苷酸。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-05-07 DOI: 10.1080/1061186X.2025.2500040

Chuanyu Zhuang, Minji Kang, Jihun Oh, Chowon Lee, Minhyung Lee

{"title":"Engineered extracellular vesicle with RAGE-antagonist peptide for delivery of anti-miRNA155 oligonucleotides to inflammatory lung cells.","authors":"Chuanyu Zhuang, Minji Kang, Jihun Oh, Chowon Lee, Minhyung Lee","doi":"10.1080/1061186X.2025.2500040","DOIUrl":"10.1080/1061186X.2025.2500040","url":null,"abstract":"Acute lung injury (ALI) is an inflammatory lung disease. In lungs afflicted with ALI, microRNA-155 (miR-155) is over-expressed, inducing pro-inflammatory cytokines by inhibition of suppressor of cytokine signalling 1 (SOCS1). In addition, receptor for advanced glycation endproducts (RAGEs) are activated, facilitating the expression of pro-inflammatory cytokines. Therefore, anti-miRNA-155 oligonucleotides (AMO155) and a RAGE-antagonist peptide (RAP) have been suggested as effective therapeutics of ALI. In this study, extracellular vesicles (EVs) were developed as a carrier of AMO155 and the RAP for a combination therapy of ALI. RAP-engineered EVs (RAP-EVs) were produced by the expression of a recombinant RAP-Lamp2b fusion protein on the surface. Then, cholesterol-modified AMO155 (AMO155c) was loaded onto the RAP-EV. In vitro assays showed that the RAP-EV delivered AMO155c as efficiently as unmodified EV (Unmod-EV). For in vivo animal experiments, AMO155c-loaded EVs (AMO155c/EVs) were administrated into the ALI models by intratracheal instillation. The results showed that the AMO155c/RAP-EV induced SOCS1 and decreased RAGE expression more efficiently than the control systems. Compared to the controls, the inflammatory responses, such as pro-inflammatory cytokines, were effectively reduced by the AMO155c/RAP-EV. The results indicated that the RAP-EV could be an efficient carrier for the combination therapy of the RAP and AMO155c.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1462-1470"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the potential of nanoemulgels for dermatological disorders. 探索纳米凝胶治疗皮肤病的潜力。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-05-06 DOI: 10.1080/1061186X.2025.2497368

Umar Abbasi, Mohd Zaid Khan, Mahak Fatima, Garima Gupta, Nagashekhara Molugulu, Amirhossein Sahebkar, Mohammed A S Abourehab, Prashant Kesharwani

{"title":"Exploring the potential of nanoemulgels for dermatological disorders.","authors":"Umar Abbasi, Mohd Zaid Khan, Mahak Fatima, Garima Gupta, Nagashekhara Molugulu, Amirhossein Sahebkar, Mohammed A S Abourehab, Prashant Kesharwani","doi":"10.1080/1061186X.2025.2497368","DOIUrl":"10.1080/1061186X.2025.2497368","url":null,"abstract":"Background and purpose: Nanoemulgels are an advanced innovation in dermatological formulations designed to treat various skin diseases. By combining the advantages of hydrogels and nanoemulsions, these hybrid systems optimise drug delivery and improve therapeutic results. Because of their nanoscale droplets, nanoemulsions improve solubility by increasing surface area and stability and bioavailability of medications.Methods and results: When embedded in a hydrogel matrix, their transformation into nanoemulgels, provide regulated and prolonged drug release, ensuring sustained therapeutic action. The ability of nanoemulgels to penetrate deeply into the layers of skin and get past obstacles like the stratum corneum to improve drug penetration and efficacy makes them highly effective in dermatology. Since the gel component helps to reduce the surface and interfacial tension and a rise in spreading coefficient along with the viscosity. The benefits of using NEGs for external use include their thixotropic, greaseless, readily dispersed properties, longer shelf life, emollient, effortlessly removed, non-staining clear, cosmetically attractive and environment friendly characteristics.Conclusions: By providing an overview of research on nanoemulgels' permeability mechanisms, pharmacokinetics, uses, properties and the difficulties involved in topical drug delivery for skin disorders, this review emphasises the potential of these materials as topical drug delivery systems in dermatology.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1343-1365"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combating chemoresistance in breast cancer: exploring tumour microenvironment, combination therapies and drug repurposing strategies. 对抗乳腺癌的化疗耐药：探索肿瘤微环境，联合治疗和药物再利用策略。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 DOI: 10.1080/1061186X.2025.2550589

Shazia Sofi, Nusrat Jan, Gowhar Masoodi, Aijaz Ahmad Mir, Manzoor Ahmad Mir

{"title":"Combating chemoresistance in breast cancer: exploring tumour microenvironment, combination therapies and drug repurposing strategies.","authors":"Shazia Sofi, Nusrat Jan, Gowhar Masoodi, Aijaz Ahmad Mir, Manzoor Ahmad Mir","doi":"10.1080/1061186X.2025.2550589","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2550589","url":null,"abstract":"Chemoresistance in breast cancer (BC) is a challenge that remains paramount in its treatment. Since the current therapies are insufficient to address chemoresistance, more potent strategies are urgently required to enhance current treatment plans. Chemoresistance in cancer can arise from a variety of molecular mechanisms, like drug efflux, decreased drug uptake, enhanced DNA repair mechanisms, the ability of cancer cells to avoid apoptosis, tumour heterogeneity and significant alterations in the tumour microenvironment, where interactions between cancer cells, cancer-associated fibroblasts, immune cells and the extracellular matrix contribute to a supportive environment that allows tumours to survive treatment and escape therapy. The available therapeutic strategies include combination therapies, immunotherapies, epigenetic modulators and drug delivery systems based on nanoparticles are a few promising strategies towards overcoming chemoresistance. Drug repurposing provides a practical and economical means to combat resistance through FDA-approved anticancer agents. Second, the incorporation of immune checkpoint inhibitors (ICIs), PARP inhibitors and metabolic modulators enhances the efficacy of treatments even further. Here in this article, we have reviewed the latest developments in the management of chemoresistance with a focus on innovative therapeutic approaches, innovative therapies targeting the tumour microenvironment, strategic drug repurposing and meticulously designed clinical trials in the treatment of BC.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-22"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravaginal co-delivery of myoinositol and metformin via dual MPPs-loaded gel for PCOS amelioration: an in-vivo study in a rat model. 通过双mpps负载凝胶阴道内共同递送肌醇和二甲双胍以改善PCOS：一项大鼠模型的体内研究。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 DOI: 10.1080/1061186X.2025.2551321

Uzma Farooq, Nazeer Hasan, Ahsan Ali, Nazia Hasan, Sradhanjali Mohapatra, Pooja Jain, Mohd Aamir Mirza, Asgar Ali, Zeenat Iqbal

{"title":"Intravaginal co-delivery of myoinositol and metformin via dual MPPs-loaded gel for PCOS amelioration: an in-vivo study in a rat model.","authors":"Uzma Farooq, Nazeer Hasan, Ahsan Ali, Nazia Hasan, Sradhanjali Mohapatra, Pooja Jain, Mohd Aamir Mirza, Asgar Ali, Zeenat Iqbal","doi":"10.1080/1061186X.2025.2551321","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2551321","url":null,"abstract":"Polycystic ovarian syndrome is a highly prevalent, multifaceted endocrinopathy among reproductive women. Current therapies have limited therapeutic success and compliance owing to multiple complications. Here, we developed MPPs-Gel formulation for efficient targeted intravaginal delivery that addresses the complementary mechanism of insulin resistance and other associated disorders. The MPPs size was observed to be 194.1 ± 3.54 nm with the zeta potential of -6.45 mV, depicting the acceptable value providing enhanced penetration across the vaginal delivery. The study investigated the effects of the MPPs-Gel formulation on insulin resistance and reproductive health in a PCOS rat model. The oestrous cycle of rats revealed that the MPPs-Gel efficiently regulated, as validated by the presence of all the phases. Ultrasonographic study, the MPPs-Gel group demonstrated an approximately 50% reduction in ovarian size (4.8 ± 0.78 mm) in comparison to the PC group (9.2 ± 0.84 mm). Results demonstrated significant improvement in insulin sensitivity, with a notable recovery observed in the MPPs-Gel group. The findings revealed a marked reduction in serum androgen concentrations, alongside notable improvements in other endocrine hormones with enhanced regulation of the reproductive cycle and oocyte quality. Thus, our findings validated that MPPs-Gel could be a promising holistic treatment approach for the associated disorders in PCOS.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-16"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing nanotechnology for enhanced wound healing: integrating polymeric nanoparticles with rosuvastatin for targeted therapy. 利用纳米技术增强伤口愈合：整合聚合纳米颗粒与瑞舒伐他汀靶向治疗。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 DOI: 10.1080/1061186X.2025.2549579

Omnia M Sarhan, Mostafa I Gebril, Hend H Mohamed, Gamal M Gamal, Kareem A Abozaid, Esraa M Sayed, Rawan H Moustafa, Youseif A Hussein, Hazem H Elsayed, Mariam O A Hamed

{"title":"Harnessing nanotechnology for enhanced wound healing: integrating polymeric nanoparticles with rosuvastatin for targeted therapy.","authors":"Omnia M Sarhan, Mostafa I Gebril, Hend H Mohamed, Gamal M Gamal, Kareem A Abozaid, Esraa M Sayed, Rawan H Moustafa, Youseif A Hussein, Hazem H Elsayed, Mariam O A Hamed","doi":"10.1080/1061186X.2025.2549579","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2549579","url":null,"abstract":"Purpose: This study investigates the development and evaluation of rosuvastatin-loaded polymeric nanoparticles as a targeted wound-healing therapy. The work aims to overcome solubility and bioavailability limitations and to enhance therapeutic outcomes in cutaneous wound repair.Methods: Six nanoparticle formulations were prepared via the nanoprecipitation method, varying polymer type and excipient content. Particle size, polydispersity index and zeta potential were measured by dynamic light scattering, while drug-loading efficiency was determined spectrophotometrically. In vitro release study was assessed. A gel incorporated optimised formulation was evaluated in a rat excisional wound model. Wound-area reduction and healing percentages were quantified over 14 days.Results: The PVP-K90-based formulation exhibited the smallest mean diameter, narrow size distribution and high entrapment efficiency. In vitro, this system achieved higher cumulative rosuvastatin release at 24 h. In vivo, the rosuvastatin hydrogel accelerated the wound-healing cascade, achieving complete closure by day 14, with significantly greater re-epithelialisation and neovascularisation compared to controls (p < .001).Conclusions: The findings demonstrate that polymeric nanoprecipitation offers a versatile platform to tailor nanoparticle characteristics and release profiles, translating into marked improvements in wound repair. This approach holds promise for the clinical translation of statin-based nanoformulations in both acute and chronic wound management.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-11"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0